Ovarian Endometrioma Superinfected With Salmonella: Case Report and Review of the Literature

Max W. Adelman,1 Jacob H. Johnson,1,2 Elizabeth L. Hohmann,1,2 and Rajesh T. Gandhi1,3

1Department of Medicine and 2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston

We present the case of a 28-year-old woman with Salmonella serovar Schwarzengrund gastroenteritis acquired during foreign travel. Her case was complicated by superinfection of a pre-existing ovarian endometrioma with a quinolone-resistant organism; the resultant ovarian abscess ultimately required surgical removal for resolution. We review the key features of this case and the previous literature on Salmonella ovarian abscess. This report highlights (1) the potential for metastatic spread of Salmonella to the ovary in women with pre-existing cysts or endometriomas and (2) the increasing worldwide burden of quinolone-resistant Salmonella.

Keywords. ovarian abscess; quinolone resistance; Salmonella; travel medicine.

CASE REPORT

A 28-year-old woman with an ovarian cyst presented with 2 weeks of diarrhea, abdominal pain, and fevers after traveling to the United Arab Emirates (UAE). One year before admission, she developed occasional sharp left lower quadrant abdominal pain and was diagnosed with an ovarian cyst. One month before admission, she traveled to the UAE for 1 week. While there, she stayed mainly in large cities, but she did travel once to a rural area where she was exposed to camels. She did not eat any unpasteurized milk, cheese, raw meat, or vegetables, and she drank only bottled water.

One week after returning, she developed nonbloody diarrhea that occurred 5–7 times per day and was associated with crampy abdominal pain and fevers to 103°F. She took oral ciprofloxacin for 3 days with incomplete resolution of symptoms.

One week later she was admitted to our hospital for further evaluation.

The patient denied sick contacts or new sexual partners. She had no significant drug or alcohol use history. She was not taking any medicines immediately before her hospitalization.

On admission, her temperature was 102.5°F and her heart rate 120 beats per minute. There was a palpable, nontender mass in her left lower quadrant. The remainder of her exam was unremarkable.

She had a white blood cell count of 22,000 cells/µL (77% neutrophils). Renal and liver function testing was normal. Computed tomography (CT) of the abdomen and pelvis demonstrated a 12-cm hypodense pelvic mass arising from one of the ovaries (Figure 1). Blood and stool cultures were drawn, and she was started on empiric intravenous (IV) ciprofloxacin and metronidazole.

After 2 days of antibiotic therapy, her fevers, diarrhea, and leukocytosis persisted. Stool cultures were positive for group B Salmonella. Out of concern for a quinolone-resistant organism, ciprofloxacin was discontinued and IV ceftriaxone was initiated. Soon thereafter (on hospital day 3), her blood cultures turned positive for group B Salmonella resistant to ciprofloxacin (minimum inhibitory concentration [MIC] = 1 µg/mL, with susceptibility defined as MIC ≤0.06 µg/mL) and susceptible to ceftriaxone (MIC ≤1 µg/mL). The blood isolate was additionally resistant to levofloxacin (MIC = 4) and susceptible to ampicillin (MIC = 4), cefepime (MIC ≤1), and trimethoprim/sulfamethoxazole (MIC ≤20). Minimum inhibitory concentration to azithromycin was 8, without defined susceptibility. Sensitivities were determined by Etest (bioMérieux, Durham, NC).

Despite treatment with ceftriaxone, her symptoms, leukocytosis, and fevers persisted. Repeat CT of the abdomen was unchanged, and further infectious studies were unremarkable. Gynecologic oncology removed a grossly infected large left ovarian abscess. Fluid cultures from this mass also grew group B Salmonella, and pathology revealed infected endometrioma.

Postoperatively, she had gradual resolution of her symptoms, leukocytosis, and fevers. She was discharged to complete 2 weeks of ceftriaxone from the date of her surgery. She was seen in outpatient follow up 2 weeks later and had no residual symptoms. After discharge the organism was speciated as Salmonella Schwarzengrund.

METHODS

We searched PubMed using Medical Subject Heading (MeSH) terms “Salmonella AND ovarian AND (cyst OR abscess)”. We identified 32 English-language cases or case series published...
since 1963 that specifically mentioned that *Salmonella* was cultured from an ovarian fluid sample [1–32]. We summarized the key features of 33 cases of *Salmonella* ovarian abscess (those identified and the case reported here).

**DISCUSSION**

This case highlights several important considerations in management of *Salmonella* gastroenteritis and bacteremia. First is the potential for metastatic infection. *Salmonella* can cause endovascular and orthopedic infections [33–35], visceral abscesses of virtually any organ [36], as well as superinfection of ovarian cysts and endometriomas (as in this case) [13, 15]. Previously reported cases of ovarian cysts and endometriomas with *Salmonella* superinfection are summarized in (Table 1).

The age range of affected patients was 2–48 years. In a large proportion (45%) of cases, there was no preceding diarrheal illness reported, and most (79%) did not have positive blood cultures for *Salmonella*. Most common *Salmonella* serovars were Enteriditis (*N* = 7) and Typhi (*N* = 6). Most commonly used antibiotics were penicillins (*N* = 8), third-generation cephalosporins (*N* = 8), and fluoroquinolones (*N* = 8). All underwent surgery, and 1 patient died. Three of 33 cases were complicated by sepsis [14, 28, 29]. There were no significant other metastatic foci of infection identified, although 2 cases had bilateral ovarian abscesses due to *Salmonella* [7, 8]; 1 patient developed findings concerning for a septic knee, but joint fluid was not sent for cultures, and her symptoms resolved with antibiotics [9].

This is the first reported case of an ovarian cyst superinfected with *Salmonella* serovar Schwarzengrund. In a 2004 study of approximately 8000 reported culture-confirmed cases of *Salmonella*, 7% of infections were invasive (infecting a normally sterile site) [35]. *Salmonella* Schwarzengrund was among the serovars least likely to cause invasive infection (14% of Schwarzengrund infections were invasive, compared with 80% and 75% for *Salmonella* serovars Dublin and Typhi, respectively).

A second important aspect of this case is the antibiotic resistance pattern (described above). The patient was initially started on empiric therapy with ciprofloxacin, but she was switched to ceftriaxone once initial cultures were positive for group B *Salmonella*. *Salmonella* resistant to quinolones has been recognized in the United States since the early 1990s [37–39], and

---

**Table 1. Reported Cases of Ovarian Cysts Superinfected With *Salmonella*, Including the Current Case, Between 1963–2016 (N = 33) [1–32]**

| Category                        | Characteristic | N (%) |
|---------------------------------|----------------|-------|
| Age range, years                | 2–48 (mean = 27) | —     |
| Comorbidity                     | None significant | 13 (39) |
|                                 | Not reported    | 13 (39) |
|                                 | SLE             | 4 (12) |
|                                 | Pregnancy       | 2 (6)  |
|                                 | RA              | 1 (3)  |
| Location                        | Asia            | 14 (42) |
|                                 | Europe          | 10 (30) |
|                                 | North America   | 6 (18) |
|                                 | Australia/New Zealand | 2 (6) |
|                                 | Africa          | 1 (3)  |
| Preceding diarrheal illness     | Yes             | 18 (55) |
| Positive blood culture          | Yes             | 7 (21) |
| Diagnostic test                 | Ultrasound      | 17 (52) |
|                                 | CT              | 8 (24) |
|                                 | Surgery         | 6 (18) |
|                                 | Radiograph      | 1 (3)  |
|                                 | Not reported    | 1 (3)  |
| Ovarian pathology               | Endometrioma    | 12 (36) |
|                                 | Teratoma        | 8 (24) |
|                                 | Other/nonspecific | 7 (21) |
|                                 | Not reported    | 6 (18) |
| *Salmonella* serovar            | Enteriditis     | 7 (21) |
|                                 | Typhi           | 6 (18) |
|                                 | Paratyphi A     | 2 (6)  |
|                                 | Typhimurium     | 2 (6)  |
|                                 | Other/unknown   | 15 (45) |
|                                 | Schwarzengrund  | 1 (3)  |
| Antibiotic used                 | Penicillin      | 8 (24) |
|                                 | 3rd-generation cephalosporin | 8 (24) |
|                                 | Fluoroquinolone | 8 (24) |
|                                 | Chloramphenicol | 5 (15) |
|                                 | Metronidazole   | 4 (12) |
|                                 | Aminoglycoside  | 4 (12) |
|                                 | Tetracycline    | 3 (9)  |
|                                 | Co-trimoxazole  | 2 (6)  |
|                                 | 1st-generation cephalosporin | 2 (6) |
|                                 | 2nd-generation cephalosporin | 2 (6) |
|                                 | 4th-generation cephalosporin | 2 (6) |
|                                 | Carbapenem      | 1 (3)  |
|                                 | Lincomycin      | 1 (3)  |
| Antibiotic duration, daysa      | 4–42 (median = 14) | —     |
| Death                           | 1 (3)           | —     |

**Abbreviations:** CT, computed tomography; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

---

*a*In some cases, more than 1 antibiotic was used.

*Indicates length of antibiotic continuation after definitive surgery. Data reported for 23 cases.

---

Figure 1. Cross-sectional imaging.
the prevalence of decreased susceptibility to ciprofloxacin in *Salmonella* has risen from 0.4% in 1996 to 4.3% in 2014 [40, 41]. Many cases are documented in travelers returning from Asia, where prevalence of decreased susceptibility to ciprofloxacin is approximately 50% in some countries, including Thailand and Taiwan [42]. There are limited data on quinolone resistance in the Middle East, where our patient likely acquired infection. Estimates of decreased susceptibility to ciprofloxacin from this region range from 2.3% (Saudi Arabia, 1999–2002) [43] to 30% (West Bank, 2005–2007) [44]. Specifically in *Salmonella* Schwarzengrund, there is concern for spread of multidrug resistance from poultry to humans in Asia and Europe [45].

**CONCLUSIONS**

This case should alert clinicians to assess patients with suspected or confirmed *Salmonella* gastroenteritis for metastatic sites of infection, including ovarian abscess in women with pre-existing cysts, and to consider resistance to commonly used antibiotics if the clinical course is not progressing as expected. Although quinolone-resistant *Salmonellae* have been recognized for approximately 30 years, the prevalence of this resistance pattern is increasing worldwide, and emerging in the Middle East, and should be considered in travelers returning from this region.

**Acknowledgment**

**Potential conflicts of interest.** All authors: No reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Hingoran V, Narula RK, Bhaala S. *Salmonella typhi* infection in an ovarian dermoid. Obstet Gynecol 1963; 22:118–20.

2. Brede MC, Garcia-Bunuel R. *Salmonella* infection in an ovarian dermoid cyst in pregnancy: report of a case. Obstet Gynecol 1964; 24:279–80.

3. Sidahmed H, Hassan A. *Salmonella* infection of ovarian dermoid cyst. Br Med J 1975; 3:140.

4. Nuttall ID, Wilson PD, Mandal BK. A suppurative ovarian cyst in pregnancy due to *Salmonella typhi*. Scand J Infect Dis 1980; 12:311–2.

5. Maggiolo E, Montanari M, Dieta A, Torre D. The suppurative abscess of an endometriotic ovarian cyst due to *Salmonella brandenburg*. Infection 1982; 10:172.

6. Evans-Jones JC, French GL. An ovarian cyst infected with *Salmonella typhi*. Case report. Br J Obstet Gynaecol 1989; 93:60–2.

7. Saltzman DH, Evans MI, Robichaux AG, et al. Nongonococcal pelvic abscess caused by *Salmonella schwarzengrund*. Clin Infect Dis 2004; 38(Suppl 3):S149–56.

8. Hoff E, Nayeri F. Splenic abscess due to *Salmonella enteritidis* in an healthy individual returning from Bali. BMJ Case Rep 2015; 2015:bcr2015212969.

9. Goyal A, Sooch N, Gupta MK, Kapoor HK. Salmonellosis of benign cystic teratoma. J Obstet Gynaecol India 1997; 41:465–7.

10. Thomas IL. *Salmonella* ovarian abscess. Aust N Z J Obstet Gynaecol 1989; 29:272–4.

11. Kemmann E, Cummins L, Dietzel H. *Salmonella* abscess in an ovarian endometrioma. N J Med 1993; 90:596–7.

12. Lalitha MK, John R. Unusual manifestations of salmonellosis—a surgical problem. Q J Med 1994; 87:301–9.

13. Chiwa LM, Ergeneli M, Santisteban J. *Salmonella* abscess of the ovary. Am J Obstet Gynecol 1995; 172:215–6.

14. Li EK, Cohen MG. Nontyphoidal *Salmonella* ovarian abscess in systemic lupus erythematosus. J Rheumatol 1995; 22:575–6.

15. Burgmans IP, Van Erp EJ, Brimicombe RW, Kazzaz BA. *Salmonella enteritidis* in an endometriotic ovarian cyst. Eur J Obstet Gynecol Reprod Biol 1997; 72:207–11.

16. Matsubayashi T, Halajima T, Asano K, et al. *Salmonella* infection of an ovarian dermoid cyst. Pediatr Int 2001; 43:164–5.

17. Tohya T, Yoshimura T, Onoda C. Unilateral ovarian abscess caused by *Salmonella*. Infect Dis Obstet Gynecol 2003; 11:217–9.

18. Chiu HY, Chiang PC, Chen KC. Ovarian abscess from *Salmonella*: a case report. J Reprod Med 2004; 49:762–4.

19. Latawiecz-Mazurkiewicz I, Juzwikiewicz P, Pasanowska J, et al. Tumour-like inflammatory abdominal conditions in children. Eur J Pediatr Surg 2005; 15:38–43.

20. Lin YH, Chen CP, Chiang S, Chen TC. Ovarian abscess caused by nontyphoidal *Salmonella* in a woman with systemic lupus erythematosus: a case report. J Reprod Med 2005; 50:627–9.

21. Wang CN, Lai CH, Hshue S, Chou HH. Ovarian endometrioma complicated by a *Salmonella* abscess caused by an enteroviral infection: a case report. J Reprod Med 2005; 50:871–3.

22. Miller AS, Hunstad DA. *Salmonella* ovarian abscess in an adolescent. Pediatr Infect Dis J 2007; 26:548–9.

23. Alonso D, Murox J, Ruiz J, et al. *Salmonella* ovarian abscess following traveling diarrhoea episode. Arch Gynecol Obstet 2007; 276:531–3.

24. Thaneemalai A, Asma H, Savithri DP. *Salmonella* tuboovarian abscess. Med J Malaysia 2007; 62:422–3.

25. Chao A, Chao AS, Wang TH, et al. Management of *Salmonella* ovarian abscess in a patient with systemic lupus erythematosus. Fertil Steril 2009; 92:9.1.e1–3.

26. Manning S, Saridogan E. *Tubo-ovarian abscess*: an unusual route of acquisition. J Obstet Gynaecol 2009; 29:355–6.

27. Gorkise NM, Osekovic S, Bot I. *Salmonella* ovarian abscess in young girl presented as acute abdomen—case report. Coll Antropol 2011; 35:223–5.

28. Kulesria R, Gupta D. Pelvic *Salmonella* infection masquerading as gynecologic malignancy. Obstet Gynecol 2011; 118:475–7.

29. Guler S, Oksuz H, Cenit GY, Kologlu OE. Bilateral tubo-ovarian abscess and sepsis caused by *Salmonella* in patients with systemic lupus erythematosus. BMJ Case Reports 2013; pii: bcr2013200187-bcr2013200187. doi: 10.1136/bcr-2013-200187.

30. Inoue M, Yanahara N, Okamoto A. *Salmonella* ovarian abscess in a patient with rheumatoid arthritis (RA): a case report with literature review. Clin Exp Obset Gynecol 2014; 41:465–7.

31. Farrant M, Bhally H. *Salmonella paratyphi* A-infected ovarian cyst in returning traveller—an unusual complication of enteric fever. N Z Med J 2014; 127:111–4.

32. Selvam EM, Sridevi TA, Menon M, et al. A case of *Salmonella enterica serovar Typhi* tubo ovarian abscess. J Obstet Gynaecol India 2015; 65:278–80.

33. Benenson S, Raveh D, Schlesinger Y, et al. The risk of vascular infection in adult patients with non-typhoidal *Salmonella* bacteremia. Am J Med 2001; 110:60–3.

34. Cheng WL, Li CW, Li MC, et al. *Salmonella* infective endocarditis. J Microbiol Immunol Infect 2014; 49:313–20.

35. Vugia DJ, Samuel M, Farley MM, et al. Invasive *Salmonella* infections in the United States, FoodNet, 1996–1999: incidence, serotype distribution, and outcome. Clin Infect Dis 2004; 38(Suppl 3):S149–56.

36. Hoff E, Nayeri F. *Salmonella* infection of ovarian dermoid cyst. Obstet Gynecol 1984; 64:585–6.

37. Herikstad H, Hayes P, Mokhtar M, et al. Emerging quinolone-resistant *Salmonella* enterica serovar Typhi and Asialoeng G glycocalyx in patients with systemic lupus erythematosus. BMJ Case Reports 2015; 2015:bcr2015212969.

38. Cherubin CE, Eng RH. Quinolones for the treatment of infections due to *Salmonella*. Rev Infect Dis 1983; 5(Suppl 1):S1–28.

39. Li EK, Cohen MG. Nontyphoidal *Salmonella* abscess in pregnancy due to *Salmonella schwarzengrund*. Clin Infect Dis Obstet Gynecol 2001; 13:726–31.

40. Panhotra BR, Saxena AK, Al-Ghamdi AM. Emerging nalidixic acid and ciprofloxacin resistance in non-typhoidal *Salmonella* isolated from patients having acute diarrhoeal disease. Ann Saudi Med 2004; 24:270–2.

41. Al-Dawadi R, Farraj MA, Essawi T. Antimicrobial resistance in non-typhoidal *Salmonella enterica* isolated from humans and poultry in Palestine. J Infect Dev Ctries 2012; 6:132–6.

42. Aarestrup FM, Hendriksen RS, Lockett J, et al. International spread of multidrug-resistant *Salmonella* Schwarzengrund in food products. Emerg Infect Dis 2007; 13:726–7.